ArticleEULAR rheumatology open2026
Usefulness of the illustrated patient-reported outcome tool 'Okomarigoto Sheet' for symptom expression and communication in patients with rheumatoid arthritis.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate whether the 'Okomarigoto Sheet' (OS), an illustration-based tool for patients with rheumatoid arthritis (RA), correlates with conventional measures and elicits patient symptoms. Methods: The OS includes 3 symptom scales: morning stiffness duration, and visual analogue scale (VAS) for joint pain and VAS for fatigue. Five illustrations depicting 5 different situations for each symptom were also scored (0 = none, 1 = present, and 2 = severe, respectively). Patients with RA were recruited from 4 Japanese clinics. Correlations between the OS and conventional RA-related measures were assessed using Spearman's rank correlation. Results: Eighty patients with RA participated in this study. The total score of all 15 illustrations positively correlated with the Disease Activity Score using the Clinical Disease Activity Index and negatively with the physical and mental component scores of the Short-Form-12. Stiffness duration, pain VAS, and fatigue VAS were each positively correlated with the respective total of 5 illustrations. Among patients scoring 0 on stiffness duration, pain VAS, or fatigue VAS, a total of 10 patients showed symptoms in the corresponding illustrations. Patient global assessment (PGA) was correlated with the total score of 5 illustrations for each of the 3 symptoms, whereas evaluator global assessment (EGA) correlated only with those for stiffness and pain, not fatigue. Conclusions: The OS reflected standard measures of disease activity and quality of life. It also has the potential to clarify symptoms that are not captured by conventional measures. Furthermore, the OS suggested that fatigue may be one of the factors contributing to the discrepancy between PGA and EGA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.